Back to search
FDAFDA · Food and drugs·Recall number D-0879-2023

Endometrin (progesterone) Vaginal Insert 100mg, packaged in a carton of 21 vaginal inserts with 21 disposable vaginal applicators, Manufactured for: Ferring Pharmaceuticals Inc., Parsippany, NJ NDC# 55566-6500-03

Published July 5, 2023 · Recall initiated: June 12, 2023

Summary

FDA records drug Class II recall D-0879-2023, published July 5, 2023 and initiated June 12, 2023. Recalling firm: Ferring Pharmaceuticals Inc; Status: Terminated; Reported quantity: N/A; Lot: AA200A, AA201A, Exp. 12/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ferring Pharmaceuticals Inc
Distributor
USA Nationwide
Lot
AA200A, AA201A, Exp. 12/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Endometrin (progesterone) Vaginal Insert 100mg, packaged in a carton of 21 vaginal inserts with 21 disposable vaginal applicators, Manufactured for: Ferring Pharmaceuticals Inc., Parsippany, NJ NDC# 55566-6500-03 recalled?

Yes. FDA published recall D-0879-2023 on July 5, 2023. Reported hazard: cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

What should I do if I have this product?

Stop using or selling the product and check the official FDA notice (D-0879-2023) for return or repair instructions.